Search
TL-895
go.drugbank.com/drugs/DB16471InvestigationalTL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively. … TL-895 is under investigation in several clinical trials for its safety and efficacy in various conditions: NCT04419623 (completed, COVID-19 in cancer patients), NCT02825836 (active, not recruiting, B
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesErlotinib
go.drugbank.com/drugs/DB00530ApprovedInvestigationalThis finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders. … Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesSynonyms: [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amineSulfadimethoxine
go.drugbank.com/drugs/DB06150ApprovedVet approvedWithdrawnIt is widely available in Russia as an over-the-counter drug manufactured by a number of Russian pharmaceutical companies.
Mixtures: TP-SULTRIXIN 40/200MG/ML SOLUTIONCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 Enzyme InhibitorsHuman thrombin
go.drugbank.com/drugs/DB11571ApprovedInvestigationalHuman thrombin is a sterile solution, pH 6.8-7.2, containing highly purified human thrombin for the activation of clotting.
Mixtures: EVICEL Fibrin Sealant (Human) Solution, 50-90 mg/ml, 800-1200 IU/mlBurosumab
go.drugbank.com/drugs/DB14012ApprovedInvestigationalThis is the first drug approved to treat adults and children ages 1 year and older with X-linked hypophosphatemia (XLH), which is a rare, inherited form of rickets. … X-linked hypophosphatemia causes low circulating levels of phosphorus in the blood.
Products: CRYSVITA ® SOLUCION PARA INYECCIÓN 10MG/ML, CRYSVITA® SOLUCIÓN PARA INYECCIÓN 20 MG/MLRitlecitinib
go.drugbank.com/drugs/DB14924ApprovedInvestigationalRitlecitinib (PF-06651600) is a highly selective inhibitor of Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsPrednicarbate
go.drugbank.com/drugs/DB01130ApprovedIL-1a is also found in fibroblasts, where it is responsible for proliferation, collagenase induction and IL-6 synthesis, which are related to skin thickness.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersDiatrizoate
go.drugbank.com/drugs/DB00271ApprovedVet approvedA commonly used x-ray contrast medium. As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.
Mixtures: Peritrast 180mg Jod/ml - Lösung zur parenteralen Anwendung, UROGRAFIN %76 IV ENJEKSIYON VE INFUZYON ICIN COZELTI, 50 MLCategories: X-Ray Contrast Activity, X-Ray Contrast Media, IodinatedDFV890
go.drugbank.com/drugs/DB16461InvestigationalDFV890 is under investigation in multiple clinical trials for its efficacy, safety, and tolerability across various conditions: NCT06031844 (coronary heart disease with elevated hsCRP), NCT04886258 (symptomatic knee osteoarthritis), NCT0...
WL-1002
go.drugbank.com/drugs/DB05346ExperimentalWL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.